Research brief
A recent clinical trial examined how thiamin and folic acid affect cognitive impairment in patients undergoing maintenance hemodialysis. Over 96 weeks, 215 participants aged 18 to 75 were studied. Those who received vitamin supplements showed notable cognitive improvements compared to those on a placebo. The study also recorded fewer cardiovascular and cerebrovascular incidents in the treatment group, suggesting that these vitamins might be a promising strategy for managing cognitive decline in this patient group.
Key points
- 215 patients took part in the study.
- Significant cognitive improvements were noted.
- Fewer adverse events occurred in the treatment group.
Study Design and Participants
This study was a prospective, randomized, double-blind, placebo-controlled trial that looked at the effects of thiamin and folic acid on cognitive impairment in patients on maintenance hemodialysis. A total of 215 patients, aged 18 to 75, participated. They were randomly assigned to receive either a daily dose of oral thiamin (90 mg) and folic acid (30 mg) or a placebo for 96 weeks.
Cognitive and Biochemical Outcomes
The main outcome measured was the change in scores on the Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-Cog). After 96 weeks, those in the treatment group showed significant improvements in their ADAS-Cog scores, unlike the placebo group. The treatment group also had higher blood levels of thiamin and folate and lower homocysteine levels.
Safety and Adverse Events
Mortality rates were similar in both groups, but the treatment group experienced fewer adverse events. there was a significant reduction in cardiovascular and cerebrovascular events among those receiving the vitamin supplements. These findings highlight the safety and potential cognitive benefits of thiamin and folic acid for patients on maintenance hemodialysis.
Discover more from Neurospan
Subscribe to get the latest posts sent to your email.
